Wockhardt Pharmaceuticals Generic drugs

Wockhardt Pharmaceuticals

This pharmaceutical concern begins its story in the early 1960s. Nowadays, it is a global corporation with subsidiaries in its home country, India, United Kingdome, Ireland, France, and the U.S. and a staff of almost 9,000 employees. More than 70% of the company’s revenue is gained through the international sales in the twenty countries it is present: the countries where the subsidiaries are operating, Russia, Brazil, Mexico, Sri Lanka, Lebanon, and many others.

Brief company history

The history of this drug-making company begins in 1959 when Doctor Habil Khorakiwala purchased Worli Chemical Works enterprise. In 1960, he restructured it into a pharmaceutical company.

The company continuously expanded through the acquisitions of other smaller pharma companies, laboratories, and research centers including the ones situated outside of the company’s home country. For instance, the company acquired Wallis Laboratory in United Kingdome and Merind Company in India in 1998; in 2003, the company acquired CP Pharmaceuticals, UK; in 2004, Wockhardt Pharmaceuticals purchased Espharma GmbH, Germany; in 2006 the new acquisitions of Dumex India, and Pinewood Laboratory in Ireland were made. The latest acquisitions were made in 2007 and are Morton Grove Company, US, and Negma, France. Following the last acquisitions, the founder of the company resigned from the president’s post and proposed his soon as a replacement.

Status/Status Date:

REGISTERED, 8/7/2012, Estimated Renewal Deadline: August 7, 2018

Serial Number:

85327885

Filing Date:

5/23/2011

Registration Number:

4185075

Goods and Services:

House mark for a full line of medicinal and pharmaceutical preparations for the treatment of human beings and animals

Mark Description:

The mark consists of the word "WOCKHARDT" in stylized letters with two overlapping partially shaded triangles to the upper left of the word.

Type Of Mark:

TradeMark

Published For Opposition Date:

5/22/2012

Last Applicant/Owner:

Wockhardt Limited, Mumbai

Mark Drawing Code:

Drawing/Design + Words

Design Search:

Triangles with bars, bands and lines (Geometric figures and solids - Triangles), Two Triangles (Geometric figures and solids - Triangles), Triangles touching or intersecting (Geometric figures and solids - Triangles), Triangles with one or more curved sides (Geometric figures and solids - Triangles)

Principal

Disclaimer:

(NOT AVAILABLE)

Correspondent:

NICOLE K. MCLAUGHLIN, DUANE MORRIS LLP, 30 S 17TH ST FL 5, PHILADELPHIA, PA 19103-4196

Wockhardt goods and services

The concern specializes in the bulk creation of active pharmaceutical ingredients, generic medications, vaccines, biopharmaceutical formulations, branded finished dosage products, and finished dosage forms for other companies as a contract manufacturer.
Besides developing and manufacturing goods, the concern has also created a network of hospitals in India that render specialized high-quality care in the areas of heart diseases, orthopedics, neurological diseases, gastrointestinal tract diseases, urological diseases, aesthetics surgery, and non-invasive surgeries. Wockhardt Pharmaceuticals opened its first hospital in 1990 and now has nine hospitals across India.

Manufacturing capacities of the concern

The drug-maker has fourteen facilities in total that are manufacturing pharma and biopharma formulations, APIs, and vaccines. The factories work for the own company’s brands and as a contractor manufacturer for other companies.

The company has the capacity to produce medications in all possible forms: tablets, capsules, powders, sachets, liquids, suspensions, creams, ointments, gels, SVP, LVP, PFS, ophthalmic solutions, lyophilized products, injectable solutions and powders, solutions for intravenous infusions, and vaccines.

Since the company is clearly targeted on the international markets of the developed countries, it has heavily invested in the update of the existing facilities and their adaptation to the strictest international norms. Currently, all of the Wockhardt Pharmaceuticals facilities are approved by the US FDA, UK MHRA and are EMEA compliant (approved for the markets of Europe, the Middle East, and Africa).

Besides the standard products, the company’s advanced biotechnological plant in Aurangabad has six new production facilities for biopharmaceutical goods and recombinant formulations.

With the increasing need for contract production, the company proceeds to upgrade its plants and further invests in new units and procedures. For instance, the recently launched modern lyophilization unit at Shendra factory is the first fully-automated facility in Asia. The plant is able to produce high volumes of highest-quality injectable products without the participation of people. There is also another plant in Aurangabad that is engaged in the production of innovational nanoparticles.

Research and development

The drug-maker’s Research and Development department has three main priorities: generics, new drug discovery, and biotechnological products development. The company has gained a reputation of an advanced company by developing patented modified release formulations and recombinant biotechnology products.

The department engages in the research work more than 600 scientists including over eighty doctors. The focus areas of the work are the fields of pharmaceutical research including innovational medication delivery systems, development of completely new medicines, API research, and biotechnology and genomics research.

Based on its research, the company filled over 1,500 patents 230 of which have been granted already.

The pioneering work of the corporation in the field of biotechnology has yielded the launch of 4 top medications – a replacement of insulin with a longer effect, recombinant insulin, erythropoietin, and hepatitis B vaccine.

The new medications development team of the company has been working on a number of lead molecules, mainly in the area of antibacterial medications that are currently at various stages of development.

The diligent research and success in the creation of new medications and novel medication delivery system have been recognized by the Indian government and noted with the award for the largest number of ‘Patent filings and Grants from India’ given to Wockhardt Pharmaceuticals for two consecutive years.

Social contribution of Wockhardt Pharmaceuticals

Besides being recognized in India as one of the best employees or the best place to work in due to the company’s policies aimed at the maximum improvement of the employees’ safety and comfort at work, the company also contributes to the whole Indian society through its community care Wockhardt foundation. The foundation initiates and sponsors numerous healthcare, educational, and environmental programs. Some of them are: 1000 Mobile, a program providing a thousand of mobile vans in which doctors travel to the distant Indian rural areas and provide primary healthcare; Wockhardt + Health Centers, a program that sponsors hospitals in need; Little Hearts program aimed at helping children with congestive heart failure; Pronto Toilet program is aimed at the creation of public areas to reduce the street and environment contamination; E-learning program for middle-school children; and many other programs about which you can find our reading the company’s official website.

Wockhardt Pharmaceuticals medications you can purchase at Rxshopmd.com

Our online drugstore product range is continuously updated. Today, we offer you the following Wockhardt Pharmaceuticals drugs:
- Aldomet (Methyldopa) is a hypotensive medication that affects the central mechanisms of blood pressure regulation. Methyldopa is converted into alpha-methylnoradrenaline, which stimulates the alpha2-adrenoreceptors of the presynaptic membrane of the neurons of the vasomotor center of the medulla oblongata and inhibits sympathetic pulsation to the vessels. The medication is appointed for the treatment of hypertension of mild to moderate severity. It can be found in our Blood pressure medications section.
- Capoten (Captopril) is one of the preparations of the group of angiotensin-converting enzyme inhibitors that reduces the formation of angiotensin II from angiotensin I. Reducing angiotensin II leads to a direct decrease in the release of aldosterone. This reduces the total peripheral resistance, blood pressure, post- and preload on the heart. The medication is indicated in arterial hypertension (including renovascular), chronic heart failure (in complex therapy), left ventricular dysfunction after myocardial infarction in patients who are clinically stable, and for diabetic nephropathy. You can find this medication in our Blood pressure medications section.

Please purchase any medications online responsibility only after your doctor prescribes you the therapy. We offer you to buy all drugs without prescriptions but insist that you start using them only if your doctor approves. Besides, you have to make sure to check the dosage per pill before you buy the pills so that their dosage would correspond to your doctor’s indications.